Vestalin (with EE)|
Norvinodrel; Vinylestrenolone; Vinilestrenolone; Vinylnoretynodrel; 17α-Vinylestr-5(10)-en-17-ol-3-one; 17α-Vinyl-δ5(10)-19-nortestosterone|
|Chemical and physical data|
|3D model (JSmol)||
Norgesterone, also known as norvinodrel or vinylestrenolone and sold under the brand name Vestalin, is a progestin medication which was formerly used in birth control pills for women but is now no longer marketed. It was used in combination with the estrogen ethinylestradiol. It is taken by mouth.
Norgesterone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has no androgenic activity.
Norgesterone was first described in 1962. It is no longer available.
Norgesterone was used in combination with ethinylestradiol in birth control pills to prevent pregnancy. It is no longer available.
Norgesterone is a progestogen, and hence is an agonist of the progesterone receptor. Unlike related progestins, it is virtually devoid of androgenic activity in animal assays.
Norgesterone, also known as 17α-vinyl-δ5(10)-19-nortestosterone or as 17α-vinylestr-5(10)-en-17β-ol-3-one, is a synthetic estrane steroid and a derivative of testosterone and 19-nortestosterone. Analogues of norgesterone include norvinisterone (17α-vinyl-19-nortestosterone) and vinyltestosterone (17α-vinyltestosterone).
Norgesterone was first described in 1962.
Society and culture
Norgesterone is the generic name of the drug and its INN. It has also been referred to as norvinodrel, vinylestrenolone, and vinylnoretynodrel.
Norgesterone was marketed in combination with ethinylestradiol, an estrogen, as a birth control pill under the brand name Vestalin.
Norgesterone is no longer marketed and hence is no longer available in any country.
- ^ a b c d e J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 887–. ISBN 978-1-4757-2085-3.
- ^ a b c d Wassef SA, Sami G, Hamid EA (1970). "Effect of switching with oral contraceptives". Egypt Popul Fam Plann Rev. 3 (1): 77–93. PMID 12254511.
- ^ a b c Lars Philip Bengtsson; M. Tausk (September 1972). Pharmacology of the endocrine system and related drugs: progesterone, progestational drugs and antifertility agents. Pergamon Press.
- ^ a b c Cynthia A. Challener (1 December 2001). Chiral Drugs. Wiley. ISBN 978-0-566-08411-9.
- ^ Boris Rubio L (November 1966). "[Vinylestrenolone: a new progestational hormone. Results of its cyclic administration]". Minerva Ginecol (in Italian). 18 (21): 1215–7. PMID 5997085.
- ^ Samaja, B. A., & Prandini, B. (1974). The influence of estrogenic and/or progestogenic treatment on some parameters of lipid metabolism: a controlled clinical study. Endokrinologie, 63(1), 76-84. [www.popline.org]
- ^ a b c d Ruggieri, Pietro de; Matscher, Rodolfo; Lupo, Corrado; Spazzoli, Giacomo (1965). "Biological properties of 17α-vinyl-5(10)-estrene-17β-ol-3-one (norvinodrel) as a progestational and claudogenic compound". Steroids. 5 (1): 73–91. doi:10.1016/0039-128X(65)90133-9. ISSN 0039-128X.
- ^ a b [patents.google.com]
- ^ a b D'Incerti Bonini L, Pagani C (April 1962). "[Clinical investigations of the progestational activity of vinylestrenolone]". Ann Ostet Ginecol (in Italian). 84: 279–85. PMID 13883015.
- ^ a b c [www.micromedexsolutions.com]
- ^ J.P. Lavery; J.S. Sanfilippo (6 December 2012). Pediatric and Adolescent Obstetrics and Gynecology. Springer Science & Business Media. pp. 236–. ISBN 978-1-4612-5064-7.